Primary breast cancer
Conditions
Interventions
Participants in the intervention group:
Compression therapy of hands and lower limbs is performed from 15 minutes before administration of taxane to 15 minutes after the end of administration
Compress
Sponsors
Bando Hiroko
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: (1) Patients aged between 18 and 75 at the time of consent (2) Patients with. Stage1-3C primary breast cancer (3) Patients receiving taxane anticancer drugs in perioperative chemotherapy for primary breast cancer (4) Eastern Cooperative Oncoligy Group Performance Status 0 or 1 (5) Patients who can adequately answer patient questionnaires (6) Patients who understand this study and given writien consent to participate in this study
Exclusion criteria
Exclusion criteria: (1) Patients with CTCAE version 5.0 Grade2 or more peripheral neuropathy in the upper or lower limbs (2) Patients with arterial blood circulation disorders such asa arteriosclerosis obliterans (3) Patients with infectious or inflammatory diseases on the skin aroung the upper and lower limbs (4) Patients diagnosed with acute or painful deep vein thrombosis within one year of screening (5) Patients with severe congestive heart failure (6)Patients with allergies to the compression gloves or stockings used in this study (7) Patients of extremely small or large hands that deviate from the size range of elastic gloves (8) Patients of extremely small or large lower limbs that deviate from the range of medical compression stocings (9) Patients with thrombophlebitis of the superficial veins of the lower extremeties (10) Other patients that the research doctor deems i nappropriate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of peripheral neuropathy of the lower limbs of CTCAE version 5.0 Grade2 or higher at the end of four cycles of perioperative chemotherapy with taxane anticancer drugs | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Incidence of peripheral neuropathy in the hands (CTCAEv5.0 grade 2 or higher) at the end of perioperative chemotherapy using taxane anticancer drugs 2.Assessment of CIPN in the hands and lower limbs using the Patient Neurotoxicity Questionnaire (PNQ) 3.Time to onset of CIPN in the hands and lower limbs (CTCAe v5.0 Grade 2 or higher) 4.Subjective symptoms of CIPN based on patient diary PRO-CTCAE TM Japanese version 5.Grip strength 6.Evaluation of CIPN onset using vibration sense (bilateral medial malleolus, Rydel-Seiffer tuning fork) 7.Changes in PainVision scores for hands and lower limbs 8.Evaluation of chemotherapy-induced skin disorders of the hands and lower limbs using CTCAEv5.0 9.Assessment of edema by changes in hands and lower limbs circumference 10.Completion rate of compression therapy 11.Relative Dose Intensity of Taxanes 12.Correlation between compression pressure and incidence of CIPN 13.Adverse events of compression therapy | — |
Contacts
Public ContactHiroko Bando
University of Tsukuba Hospital
Outcome results
None listed